FibroBiologics wins US patent on fibroblast-assisted islet transplant engraftment for Type 1 diabetes
FBLG•US patent covers fibroblast-assisted islet transplant methods
FibroBiologics received U.S. Patent No. 12,691,147 covering use of fibroblasts to improve engraftment, survival, and function of transplanted insulin-producing islets.
The methods target early post-implant losses that limit islet transplant outcomes, aiming to boost long-term viability via improved microenvironment and vascular support.
The company said stronger engraftment could reduce donor islet requirements per patient, potentially expanding access amid limited donor pancreas supply.
